Avamys Dosage/Direction for Use

Fluticasone furoate nasal spray is for administration by the intranasal route only.
For full therapeutic benefit regular usage is recommended. Onset of action has been observed as early as 8 hours after administration. It may take several days of treatment to achieve maximum benefit. An absence of an immediate effect should be explained to the patient.
Patients should be instructed that the device must be primed: before first use, and if the cap is left off, if the device does not seem to be working, if the nasal spray has not been used for 30 days or more.
In order to prime the device, the nasal spray needs to be shaken vigorously for about 10 seconds with the cap on. This is important as fluticasone furoate is a thick suspension that becomes liquid when vigorously shaken. It will only spray when it becomes liquid.
The patient must then press the button firmly all the way in, approximately 6 times until a fine mist is seen, (to ensure a full dose is delivered).
Once primed, the patient must shake the nasal spray vigorously each time before use. The cap must be replaced after use to keep the nozzle clean and to prevent the need for re-priming.
Patients must follow the step-by-step instructions in the instruction leaflet for use and handling.
For seasonal allergic rhinitis and perennial allergic rhinitis: Adults and Adolescents (12 Years and over): The recommended starting dosage is 2 sprays (27.5 micrograms of fluticasone furoate per spray) in each nostril once daily (total daily dose, 110 micrograms).
Once adequate control of symptoms is achieved, dose reduction to one spray in each nostril once daily (total daily dose, 55 micrograms) may be effective for maintenance.
Children (2 to 11 Years of Age): The recommended starting dosage is 1 spray (27.5 micrograms of fluticasone furoate per spray) in each nostril once daily (total daily dose, 55 micrograms).
Patients not adequately responding to 1 spray in each nostril once daily (total daily dose, 55 micrograms) may use 2 sprays in each nostril once daily (total daily dose, 110 micrograms).
Once adequate control of symptoms is achieved, dose reduction to 1 spray in each nostril once daily (total daily dose, 55 micrograms) is recommended.
Children under 2 years of age: There is no experience in children under the age of 2 years.
Special patient groups: Elderly patients: No dosage adjustment required. (See Pharmacology: Pharmacokinetics: Special patient populations under Actions.)
Renal patients: No dosage adjustment required. (See Pharmacology: Pharmacokinetics: Special patient populations under Actions.)
Patients with hepatic impairment: No dosage adjustment is required at the indicated dosage in patients with hepatic impairment. (See Pharmacology: Pharmacokinetics: Special patient populations under Actions.)